The development of gene therapy: from monogenic recessive disorders to complex diseases such as cancer
- PMID: 19565894
- DOI: 10.1007/978-1-59745-561-9_1
The development of gene therapy: from monogenic recessive disorders to complex diseases such as cancer
Abstract
During the last 4 decades, gene therapy has moved from preclinical to clinical studies for many diseases ranging from monogenic recessive disorders such as hemophilia to more complex diseases such as cancer, cardiovascular disorders, and human immunodeficiency virus (HIV). To date, more than 1,340 gene therapy clinical trials have been completed, are ongoing, or have been approved in 28 countries, using more than 100 genes. Most of those clinical trials (66.5%) were aimed at the treatment of cancer. Early hype, failures, and tragic events have now largely been replaced by the necessary stepwise progress needed to realize clinical benefits. We now understand better the strengths and weaknesses of various gene transfer vectors; this facilitates the choice of appropriate vectors for individual diseases. Continuous advances in our understanding of tumor biology have allowed the development of elegant, more efficient, and less toxic treatment strategies. In this introductory chapter, we review the history of gene therapy since the early 1960s and present in detail two major recurring themes in gene therapy: (1) the development of vector and delivery systems and (2) the design of strategies to fight or cure particular diseases. The field of cancer gene therapy experienced an "awkward adolescence." Although this field has certainly not yet reached maturity, it still holds the potential of alleviating the suffering of many individuals with cancer.
Similar articles
-
[Adenovirus vectors and their clinical application in gene therapy].Orv Hetil. 2001 Sep 23;142(38):2061-70. Orv Hetil. 2001. PMID: 11697063 Review. Hungarian.
-
[Recent developments in gene therapy].Verh K Acad Geneeskd Belg. 2004;66(4):305-17; discussion 317-20. Verh K Acad Geneeskd Belg. 2004. PMID: 15553101 Review. Dutch.
-
New strategies for cancer gene therapy: progress and opportunities.Clin Exp Pharmacol Physiol. 2010 Jan;37(1):108-14. doi: 10.1111/j.1440-1681.2009.05268.x. Epub 2009 Aug 4. Clin Exp Pharmacol Physiol. 2010. PMID: 19671071 Review.
-
Beware the Medical-Industrial Complex.Oncologist. 1996;1(4):IV-V. Oncologist. 1996. PMID: 10388005
-
Progress towards gene therapy for cancer.J Exp Clin Cancer Res. 2000 Sep;19(3):261-70. J Exp Clin Cancer Res. 2000. PMID: 11144517 Review.
Cited by
-
A Brief Introduction to Current Cancer Gene Therapy.Methods Mol Biol. 2022;2521:1-21. doi: 10.1007/978-1-0716-2441-8_1. Methods Mol Biol. 2022. PMID: 35732990
-
Uncovering the Pharmacological Mechanism of 2-Dodecyl-6-Methoxycyclohexa-2,5 -Diene-1,4-Dione Against Lung Cancer Based on Network Pharmacology and Experimental Evaluation.Front Pharmacol. 2021 Feb 2;12:617555. doi: 10.3389/fphar.2021.617555. eCollection 2021. Front Pharmacol. 2021. PMID: 33613291 Free PMC article.
-
Bacteriophage Mediates Efficient Gene Transfer in Combination with Conventional Transfection Reagents.Viruses. 2015 Dec 8;7(12):6476-89. doi: 10.3390/v7122951. Viruses. 2015. PMID: 26670247 Free PMC article.
-
Bacteriophage-derived vectors for targeted cancer gene therapy.Viruses. 2015 Jan 19;7(1):268-84. doi: 10.3390/v7010268. Viruses. 2015. PMID: 25606974 Free PMC article. Review.
-
Targeting the oncogenic Met receptor by antibodies and gene therapy.Oncogene. 2015 Apr 9;34(15):1883-9. doi: 10.1038/onc.2014.142. Epub 2014 Jun 2. Oncogene. 2015. PMID: 24882574 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical